External Research News


Thursday 06 October 2016

Liver Cancer Researchers from AP-HP and Singapore Collaborate on a Prospective Meta-Analysis of Two Studies of Y-90 resin microspheres versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (HCC)
Cancer researchers from Assistance Publique – Hôpitaux de Paris (AP-HP) and The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI) announced that they will collaborate on a prospective meta-analysis that will combine the impending results of two large, randomized controlled studies of Y-90 resin microspheres versus sorafenib. The two studies, which have completed patient recruitment, enrolled approximately 800 patients with advanced primary liver cancer (hepatocellular carcinoma or HCC).
Read more


Download PDF Download PDF

Languages:

Monday 06 June 2016

SIRveNIB, a Major Primary Liver Cancer Study in the Asia-Pacific Region, Completes Enrolment
The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore, Singapore Clinical Research Institute (SCRI) and Sirtex Medical Limited announced that the AHCC protocol 06 SIRveNIB randomised controlled study of SIR-Spheres Y-90 resin microspheres versus sorafenib in the treatment of unresectable primary liver cancer (hepatocellular carcinoma or HCC) has completed its target enrolment of at least 360 patients.
Read more


Download PDF Download PDF

Languages:

Monday 07 March 2016

Major Liver Cancer Study Completes Palliative Cohort Enrolment
Palliative Group of SORAMIC Study on Treatment of Locally Advanced Primary Liver Cancer with SIR-Spheres® Y-90 resin microspheres followed by Sorafenib Reaches 420-patient Enrolment Target
Read more


Download PDF Download PDF

Languages:

Wednesday 04 March 2015

Treatment of primary liver cancer: SARAH study completes enrolment, results expected late 2016.
Launched by the Assistance Publique – Hôpitaux de Paris in December 2011, 'SARAH' – the French national collaborative randomized controlled study of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled more than 400 patients; results expected late 2016.
Read more


Download PDF Download PDF

Languages:

Thursday 21 November 2013

Ten-year Clinical Experience Shows Yttrium-90 microspheres Achieve Local Control of Liver Cancer in over 80% of Patients at Clínica Universidad de Navarra (CUN)
Ten years ago CUN became European pioneer in the use of radioembolization, or Selective Internal Radiation Therapy (SIRT) with SIR-Spheres® microspheres, for the treatment of liver tumours. It is the Spanish medical center most experienced in this therapy, which has been used in over 400 patients.
Read more


Download PDF Download PDF

Languages:

Thursday 20 June 2013

Older Liver Cancer Patients Respond to Radioembolisation Using SIR-SPHERES Equally as well as Younger Patients, New Study in Journal of Hepatology Says
Based on New Data from Multi-Centre ENRY Evaluation of 325 Patients, Authors Suggest that Radioembolisation May Be a Well-Tolerated and Effective Option for an Increasing Population of Older Patients
Read more
Attachment(s):
Bruno Sangro MD


Download PDF Download PDF

Languages:

Thursday 20 June 2013

Treatment of Primary Liver Cancer: SARAH Study Now Available for All Eligible Patients Throughout France
Launched by the Assistance Publique - Hôpitaux de Paris (AP-HP) in December 2011, SARAH, a French National Collaborative Randomized Controlled Trial of Radioembolization with yttrium-90 resin microspheres versus Sorafenib in Advanced Hepatocellular Carcinoma Seeks to Enroll 400 Patients
Read more


Download PDF Download PDF

Languages:

Thursday 30 May 2013

SIR-Spheres® microspheres as Effective and Safe in the Elderly as they are in Younger Patients with Colorectal Liver Metastases According to Data Released at ASCO Annual Meeting
Landmark Analysis Provides Key Insights Into Treatment Pathways for Patients Aged 70 and Older
Read more

Friday 19 October 2012

Study Demonstrates Radioembolization Using SIR-Spheres Significantly Improves Overall Survival for Patients with Inoperable Colorectal Cancer
Survival of Patients Treated with SIR-Spheres More than Double that of Patients Who Received Best Supportive Care, Benefit Rivals That Found With New Biological Agents, Authors Note
Read more

Tuesday 01 May 2012

Steve Biko Academic Hospital is the First in South Africa to Treat Liver Tumours with Sir-Spheres microspheres
On Tuesday 24th April two South African patients were treated at Steve Biko Academic Hospital, Pretoria, with selective internal radiation therapy (SIRT) in the form of SIR-Spheres microspheres (yttrium-90 resin microspheres; Sirtex Medical Limited, Sydney, Australia) – an innovative form of internal radiotherapy for liver cancers. This form of liver radiotherapy has been shown to be effective in treating patients with different forms of inoperable liver tumours.
Read more

Friday 23 March 2012

Largest Comparative Study of Radioembolisation Showes SIR-SPHERES Microspheres Significantly Improves Survival for Cancer Patients with Inoperable Liver Tumors
New Australian data provides further evidence of survival benefit for radioembolisation
Read more

Friday 03 February 2012

New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients
‘SARAH’ – a French National Collaborative Randomized Controlled Trial of Radioembolization with yttrium-90 resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma is now Open for Recruitment
Read more


Download PDF Download PDF

Languages:

Thursday 07 July 2011

Largest Multi-Centre Evaluation of Radioembolisation Using SIR-Spheres For Patients with Inoperable Primary Liver Cancer Published in Hepatology
ENRY Evaluation in 325 Patients Affirms Efficacy and Safety of Radioembolisation in Seriously-ill Patients and Identifies Specific Populations who may Benefit from Treatment
Read more


Download PDF Download PDF

Languages:

Thursday 07 July 2011

Largest Multi-Centre Evaluation of Radioembolisation Using SIR-Spheres For Patients with Inoperable Primary Liver Cancer Published in Hepatology
Background information to support the results of the ENRY study
Read more


Download PDF Download PDF

Languages:

Thursday 19 August 2010

Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of Cancer.[1]
Read more

Monday 02 June 2008

Study Suggests Survival Benefit from Radioactive Microsphere Therapy in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
Radioactive microspheres appear to be a safe and effective treatment for patients with colorectal cancer that has spread to the liver and who have failed available chemotherapy options, according to the results of a prospective clinical study presented today at the 44th American Society of Clinical Oncology (ASCO) conference.[1]   The multicentre phase II study was conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) using SIR- Spheres, which are tiny resin microspheres labelled with radioactive yttrium-90.
Read more

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×